Effect of sucralfate on gastric permeability in an ex vivo model of stress‐related mucosal disease in dogs

Background Sucralfate is a gastroprotectant with no known systemic effects. The efficacy of sucralfate for prevention and treatment of stress‐related mucosal diseases (SRMD) in dogs is unknown. Hypothesis/Objectives To develop a canine ex vivo model of SRMD and to determine the effect of sucralfate...

Full description

Saved in:
Bibliographic Details
Published in:Journal of veterinary internal medicine Vol. 32; no. 2; pp. 670 - 678
Main Authors: Hill, Tracy L., Lascelles, B. Duncan X., Blikslager, Anthony T.
Format: Journal Article
Language:English
Published: United States John Wiley and Sons Inc 01-03-2018
Wiley
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Sucralfate is a gastroprotectant with no known systemic effects. The efficacy of sucralfate for prevention and treatment of stress‐related mucosal diseases (SRMD) in dogs is unknown. Hypothesis/Objectives To develop a canine ex vivo model of SRMD and to determine the effect of sucralfate on mucosal barrier function in this model. Animals Gastric antral mucosa was collected immediately postmortem from 29 random‐source apparently healthy dogs euthanized at a local animal control facility. Methods Randomized experimental trial. Sucralfate (100 mg/mL) was applied to ex vivo canine gastric mucosa concurrent with and after acid injury. Barrier function was assessed by measurement of transepithelial electrical resistance (TER) and radiolabeled mannitol flux. Results Application of acidified Ringers solution to the mucosal side of gastric antrum caused a reduction in gastric barrier function, and washout of acidified Ringers solution allowed recovery of barrier function (TER: 34.0 ± 2.8% of control at maximum injury, 71.3 ± 5.5% at recovery, P < .001). Sucralfate application at the time of injury or after injury significantly hastened recovery of barrier function (TER: 118.0 ± 15.2% of control at maximum injury, P < .001 and 111.0 ± 15.5% at recovery, P = .35). Conclusions and Clinical Importance Sucralfate appeared effective at restoring defects in gastric barrier function induced by acid and accelerating repair of tissues subjected to acid in this model, suggesting that sucralfate could have utility for the treatment and prevention of SRMD in dogs.
Bibliography:Funding information
Novartis Animal Health; National Institutes of Health, Grant/Award Number: T32 OD011130; National Institute of Diabetes and Digestive and Kidney Diseases, Grant/Award Number: P30 DK034987
Funding information Novartis Animal Health; National Institutes of Health, Grant/Award Number: T32 OD011130; National Institute of Diabetes and Digestive and Kidney Diseases, Grant/Award Number: P30 DK034987
ISSN:0891-6640
1939-1676
DOI:10.1111/jvim.15076